James Adams

Chief Technical Officer TR1X Bio

Seminars

Thursday 25th March 2027
Advancing Off-the-Shelf Immune Tolerance with Allogeneic TR1 Cell Therapies
1:30 pm
  • Showcasing how a non-gene-edited allogeneic TR1 platform is simplifying manufacturing and broadening access to immune tolerance therapies
  • Presenting safety and translational insights challenging historical concerns around allogeneic regulatory cell therapies and GvHD risk
  • Evaluating opportunities for scalable off-the-shelf TR1 therapies to overcome cost, manufacturing, and accessibility barriers across autoimmune disease indications
James Adams